Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AFMD 
Affimed NV (AFMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/28/2025: AFMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -91.62% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.67M USD | Price to earnings Ratio - | 1Y Target Price 14.05 |
Price to earnings Ratio - | 1Y Target Price 14.05 | ||
Volume (30-day avg) 376241 | Beta 2.22 | 52 Weeks Range 0.63 - 8.95 | Updated Date 04/3/2025 |
52 Weeks Range 0.63 - 8.95 | Updated Date 04/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.92 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8709.15% |
Management Effectiveness
Return on Assets (TTM) -49.42% | Return on Equity (TTM) -149.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1365427 | Price to Sales(TTM) 2.07 |
Enterprise Value -1365427 | Price to Sales(TTM) 2.07 | ||
Enterprise Value to Revenue 13.07 | Enterprise Value to EBITDA 1.13 | Shares Outstanding 16392300 | Shares Floating 15477650 |
Shares Outstanding 16392300 | Shares Floating 15477650 | ||
Percent Insiders 6.01 | Percent Institutions 23.75 |
Analyst Ratings
Rating 4.71 | Target Price 15.02 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Affimed NV
Company Overview
History and Background
Affimed NV was founded in 2000. The company is a clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies, specifically using its ROCK platform to create novel tetravalent, bispecific antibodies.
Core Business Areas
- Innate Cell Engagers (ICE): Affimed's core business focuses on developing ICE molecules that bind to NK cells and tumor cells, triggering an anti-tumor immune response.
- ROCK Platform: The company's ROCK platform drives the discovery and development of its ICE molecules. It allows for efficient generation of novel antibody therapeutics with enhanced binding and avidity.
Leadership and Structure
Dr. Andreas Harstrick is the CEO. The company has a board of directors and operates through various functional departments including R&D, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- AFM13 (CD30/CD16A): AFM13 is Affimed's lead product candidate, a tetravalent bispecific ICE designed to target CD30, a receptor expressed on Hodgkin lymphoma and other lymphoma cells. It binds to CD16A on NK cells to trigger an anti-tumor immune response. Competition includes established chemotherapies and novel therapies like brentuximab vedotin. Currently, this treatment has not been approved, so no market share can be assessed. Competition would also come from bispecific antibodies such as Epkinly by AbbVie, and Columvi, by Roche.
- AFM24 (EGFR/CD16A): AFM24 is designed to bind to EGFR, a receptor overexpressed on many solid tumors, and CD16A on NK cells. It is in clinical development for EGFR-expressing solid tumors. Competitors include EGFR inhibitors such as cetuximab and panitumumab. Currently, this treatment has not been approved, so no market share can be assessed.
Market Dynamics
Industry Overview
The cancer immunotherapy market is rapidly growing, driven by the success of checkpoint inhibitors and other immunotherapeutic approaches. There is increasing interest in novel approaches to harness the power of the innate immune system to fight cancer.
Positioning
Affimed NV is positioned as a pioneer in developing ICE molecules. Its ROCK platform gives it a competitive advantage in generating and optimizing novel antibody therapeutics. The company is focused on niche indications and strategic partnerships to maximize its potential.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is expected to exceed $100 billion annually. Affimed is positioned within this large market, targeting specific cancer subtypes with unmet needs. Successful commercialization of its ICE molecules could capture a significant share.
Upturn SWOT Analysis
Strengths
- Novel ICE technology platform (ROCK)
- Bispecific antibody expertise
- Strong preclinical and clinical data for AFM13
- Strategic partnerships with leading pharmaceutical companies
- Experienced management team
Weaknesses
- Clinical stage company with no approved products
- Reliance on strategic partnerships for funding
- High development costs
- Uncertainty in clinical trial outcomes
- Competition from established and emerging cancer therapies
Opportunities
- Expansion of ICE platform to new targets and indications
- Potential for accelerated approval pathways for innovative therapies
- Increasing demand for novel cancer immunotherapies
- Potential for strategic collaborations and acquisitions
- Advancements in cancer diagnostics to identify patients most likely to respond to ICE therapy
Threats
- Clinical trial failures
- Competition from established and emerging therapies
- Regulatory hurdles
- Intellectual property challenges
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- XOMA (XOMA)
- MacroGenics (MGNX)
- Adaptive Biotechnologies (ADPT)
Competitive Landscape
Affimed's competitive advantage lies in its novel ICE platform and bispecific antibody expertise. However, it faces competition from larger pharmaceutical companies with more resources and established cancer therapies. XOMA and MacroGenics also develop and offer bispecific antibodies but with different therapeutic mechanisms.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Affimed's historical growth has been driven by advancing its pipeline through clinical development and securing strategic partnerships.
Future Projections: Future growth depends on the successful development and commercialization of its ICE molecules, particularly AFM13 and AFM24. Analyst estimates and revenue are based on these future milestones.
Recent Initiatives: Recent initiatives include advancing AFM13 in combination with other therapies, initiating clinical trials for AFM24, and expanding its ICE platform.
Summary
Affimed NV is a clinical-stage biopharmaceutical company with an innovative ICE technology platform. The company's success hinges on the successful development and commercialization of its lead product candidates, particularly AFM13. While promising, the company faces risks associated with clinical trials, regulatory approvals, and competition. Strategic partnerships are crucial for funding and expanding its reach.
Similar Companies
ADPT
Adaptive Biotechnologies Corp
ADPT
Adaptive Biotechnologies Corp
MGNX
MacroGenics Inc
MGNX
MacroGenics Inc
MRK
Merck & Company Inc
MRK
Merck & Company Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
XOMA
XOMA Corp
XOMA
XOMA Corp
Sources and Disclaimers
Data Sources:
- Affimed NV's Investor Relations Website
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Affimed NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-09-12 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 76 | Website https://www.affimed.com |
Full time employees 76 | Website https://www.affimed.com | ||
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.